Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 10 mg | $45.00 | In stock | TSM-2607-0008 | |
| 20MG | $70.00 | In stock | 20270701-A-B |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
Tesamorelin is a synthetic analogue of human growth hormone releasing hormone: all 44 amino acids of GHRH with a trans-3-hexenoyl group added at the N-terminus.
Identity
| Type | Synthetic peptide, 44 amino acids, N-terminal modified |
|---|---|
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5136 g/mol |
| CAS number | 218949-48-5 |
| PubChem CID | 16137828 |
Tesamorelin is the full 44-residue sequence of human growth hormone releasing hormone, GHRH(1-44), with a C-terminal amide and a trans-3-hexenoyl group attached to the N-terminal tyrosine. Molecular formula C221H366N72O67S, molecular weight 5136 g/mol (PubChem CID 16137828, CAS 218949-48-5). The single sulfur atom belongs to the methionine at position 27, which can oxidize to the sulfoxide and appear as a separate peak on HPLC. At about 5 kDa the peptide is large enough that electrospray mass spectrometry shows several charge states, from which the intact mass is calculated; this confirms both the sequence length and the presence of the N-terminal modification. It is supplied as a lyophilized powder in a sealed vial.
What the published research covers
Tesamorelin was studied in phase 3 clinical trials in adults with HIV and excess abdominal fat, published in peer-reviewed journals.
Tesamorelin was developed by Theratechnologies, under the code TH9507, as a stabilized analogue of growth hormone releasing hormone (GHRH). Natural GHRH is cleaved quickly at its N-terminus by peptidases; the trans-3-hexenoyl group added to the first tyrosine was designed to slow that cleavage while keeping the full 44-residue sequence. Its clinical program centered on adults with HIV who had accumulated visceral abdominal fat during antiretroviral therapy.
The first phase 3 trial randomized 412 adults with HIV and abdominal fat accumulation to daily tesamorelin or placebo for 26 weeks. Visceral adipose tissue measured by computed tomography fell by 15.2% in the tesamorelin group and rose by 5.0% in the placebo group; triglycerides fell, and IGF-I rose by 81% (Falutz, 2007). A pooled analysis of two phase 3 trials with 806 participants reported a treatment effect of -15.4% on visceral adipose tissue at 26 weeks, no significant change in abdominal subcutaneous fat, and no clinically meaningful difference in glucose measures at 26 and 52 weeks (Falutz, 2010). Later trials measured liver fat. A 50-person trial at Massachusetts General Hospital reported reductions in visceral fat and liver fat over six months, with a rise in fasting glucose at two weeks that was not significant at six months (Stanley, 2014). A 61-person multicenter trial in people with HIV and nonalcoholic fatty liver disease reported a 37% relative reduction in hepatic fat fraction at 12 months (Stanley, 2019). Outside HIV, a 20-week trial of 152 older adults, 66 of them with mild cognitive impairment, reported a favorable effect on a composite of cognitive tests, mainly executive function, along with a 117% rise in IGF-I (Baker, 2012).
Most of the trials were run in one population, adults with HIV on antiretroviral therapy. Visceral fat and liver fat are imaging measures, and the trials were not designed to show effects on cardiovascular events or long-term liver outcomes; the authors of the liver studies called for further studies. The cognitive trial was a single-center study whose findings have not been confirmed in larger trials. Rises in IGF-I and changes in glucose were recorded across the trials and are part of what any reading of this literature has to weigh.
Regulatory status
Tesamorelin exists as an FDA-approved prescription product. This material is not that product and is supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is tesamorelin offered in?
- Vials of 10 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is this the approved medicine?
- No. Tesamorelin is the active ingredient of Egrifta, a prescription product approved by the FDA. This material is a research peptide of the same sequence, supplied for laboratory research only; it is not that product.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Falutz J et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine. PubMed 18057338
- Falutz J et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology and Metabolism. PubMed 20554713
- Baker LD et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. PubMed 22869065
- Stanley TL et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. PubMed 25038357
- Stanley TL et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV. PubMed 31611038
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement